Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Keros Therapeutics (KROS) over the last 4 years, with Q3 2025 value amounting to -$1.4 million.

  • Keros Therapeutics' Tax Provisions changed N/A to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year change of. This contributed to the annual value of $300000.0 for FY2024, which is N/A changed from last year.
  • Per Keros Therapeutics' latest filing, its Tax Provisions stood at -$1.4 million for Q3 2025.
  • Over the past 5 years, Keros Therapeutics' Tax Provisions peaked at $10.0 million during Q1 2025, and registered a low of -$2.2 million during Q2 2025.
  • Its 3-year average for Tax Provisions is $1.2 million, with a median of $50000.0 in 2021.
  • Examining YoY changes over the last 5 years, Keros Therapeutics' Tax Provisions showed a top increase of 12906.98% in 2021 and a maximum decrease of 12906.98% in 2021.
  • Keros Therapeutics' Tax Provisions (Quarter) stood at $2.0 million in 2021, then plummeted by 84.99% to $300000.0 in 2024, then plummeted by 574.67% to -$1.4 million in 2025.
  • Its Tax Provisions was -$1.4 million in Q3 2025, compared to -$2.2 million in Q2 2025 and $10.0 million in Q1 2025.